Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-05-11

Clinical Trial Update: Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating incobotulinum toxin A (Xeomin) for focal task-specific dystonia of the musician's hand has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Dystonia | Phase 2 | Status: COMPLETED | Results posted: 2023-05-11